Cervical Cancer
Conditions
Brief summary
This was a randomized, double-blind, active-controlled, phase I/II clinical trial to enroll 200 healthy female including 80 healthy adult aged 19 to 26 years and 120 adolescents aged 9 to 13 years.
Detailed description
In order to confirm the safety, 80 healthy adult were enrolled first. Eligible subjects were randomized into 1:1 ratio to receive three doses of either test vaccine (NPB615) or comparator vaccine (Gardasil). The safety of the test vaccine (NBP615) was confirmed by 2nd vaccination in adult subjects. After that, enrolment of 120 adolescent subjects proceeded. Eligible subjects who previously agreed to participate in the study were screened and only those subjects who met the inclusion/exclusion criteria were randomized in to 1:1 to receive two doses of test vaccine (NBP615) or comparator (Gardasil pre-filled syringe). 0.5 ml Intramuscular injection at were given at each vaccination and two blood sample, pre vaccine and post vaccine 4 weeks after completion of vaccine were collected to assess the immunogenicity of NBP615 and Gardasil, comparator vaccine. Solicited adverse events occurred up to 7 days after each dose of the investigational product were collected in the diary card. Unsolicited adverse events occurred up to 28 days after each dose of the investigational product were collated in the diary card. Serious adverse events were collected during the entire study period. In addition to this safety data was collected through the study period by active contact with the study participants by doing home visit or by telephone contact.
Interventions
BIOLOGICALNBP615
Intramuscular injection, 0.5ml
BIOLOGICALGardasil
Intramuscular injection, 0.5ml
Sponsors
SK Bioscience Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
9 Years to 26 Years
Healthy volunteers
Yes
Inclusion criteria
\[Inclusion Criteria\] * Healthy adult(19 to 26 years)/adolescent(9 to 13 years) of age at the time of the 1st vaccination * Participant fully understands study procedures, and voluntarily agrees to participate in the study and follow the study procedure by giving written informed consent \[
Exclusion criteria
\] * Received a marketed Human papillomavirus(HPV) vaccine, or had participated in an HPV vaccine clinical trial and had received either active agent or placebo. * History of hypersensitivity to any component of the study vaccines. * Currently immunocompromised or was diagnosed as having a congenital or acquired immunodeficiency, Human Immunodeficiency Virus(HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, other autoimmune condition, or other immune disorder which is decided to be medically significant by the investigator. * Received immunoglobulins and/or blood product within 3 months preceding the first dose of study vaccine or planned administration during the study period. * Receiving or had received chemotherapy, immunosuppressive therapies, or radiation therapy in the year prior to enrolment. * Chronic administration (\>14 days) of immune-suppressants or immune modulating drugs within 3 months prior to the first vaccine dose or planned administration during the study period. Inhaled, nasal and topical steroids are allowed. * Participant with severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections. * Subject has active cervical disease or a significant history of cervical disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Geometric mean titer measured by Enzyme-linked Immunosorbent Assay(ELISA) | 4 weeks after the vaccination | geometric mean titer against anti-HPV 6, 11, 16, and 18 for each treatment group |
| seroconversion rate measured by Enzyme-linked Immunosorbent Assay(ELISA) | 4 weeks after the vaccination | proportion of subjects who seroconverted from seronegative at baseline to seropositive at post vaccination for anti-HPV 6, 11, 16, and 18 |
| Geometric mean titer measured by pseudovirion-based neutralization assay(PBNA) | 4 weeks after the vaccination | geometric mean titer against anti-HPV 6, 11, 16, and 18 for each treatment |
| Incidence rate of Solicited Adverse Event | 7 days after the vaccination | Solicited local/systemic adverse event after vaccination |
Countries
South Korea
Outcome results
None listed